BioCryst (BCRX) director receives RSU and option grants under board plan

Rhea-AI Filing Summary

BIOCRYST PHARMACEUTICALS director Alan G. Levin received equity awards as part of non-employee director compensation. He was granted 15,294 shares of Common Stock as Restricted Stock Units that will vest on the first anniversary of the grant date. He also received an automatic stock option grant for 33,540 shares of Common Stock at an exercise price of $8.5000 per share, expiring on June 11, 2036. Following these awards, he directly holds 79,565 shares of Common Stock.

Insights

Equity Compensation Analyst

Routine director equity grants align compensation with BIOCRYST share performance.

The filing shows non-employee director Alan G. Levin receiving 15,294 Restricted Stock Units and options for 33,540 shares at an exercise price of $8.5000. Both awards are granted under the company’s Non-Employee Director Compensation Policy.

The RSUs vest on the first anniversary of the grant date, while the options run until June 11, 2036. These awards represent standard, compensation-related acquisitions rather than open-market purchases, so they carry limited signaling value about the director’s independent view of the stock.

Insider Trade Summary

Net Buyer: 15,294 shares

Net Buy 2 txns

Insider LEVIN ALAN G

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Automatic Stock Option Grant	33,540	$0.00	$0.00
Grant/Award	Common Stock	15,294	$0.00	$0.00

Holdings After Transaction: Automatic Stock Option Grant — 33,540 shares (Direct); Common Stock — 79,565 shares (Direct)

Footnotes (2)

1. F1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
2. F2. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

Key Figures

RSU grant: 15,294 shares Option grant size: 33,540 shares Option exercise price: $8.5000 per share +2 more

5 metrics

RSU grant 15,294 shares Automatic non-employee director Restricted Stock Units grant, vests after one year

Option grant size 33,540 shares Automatic stock option grant to director on underlying Common Stock

Option exercise price $8.5000 per share Exercise price for director stock options granted on June 11, 2026

Option expiration June 11, 2036 Expiration date of director stock options

Common shares held 79,565 shares Total Common Stock directly held by director after transactions

Key Terms

Restricted Stock Units, Non-Employee Director Compensation Policy, Automatic Stock Option Grant, stock options

4 terms

Restricted Stock Units financial

"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Non-Employee Director Compensation Policy financial

"pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended"

Automatic Stock Option Grant financial

"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy."

stock options financial

"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/15/2026 - 04:29 PM Accepted by SEC EDGAR 06/15/2026 - 04:29 PM Learn about SEC filing dates

FAQ

What equity awards did BCRX director Alan G. Levin receive in this Form 4?

Alan G. Levin received 15,294 shares of Common Stock as Restricted Stock Units and an automatic stock option grant for 33,540 shares of Common Stock at an exercise price of $8.5000 per share, as part of BioCryst’s non-employee director compensation.

How many BCRX shares does Alan G. Levin hold after these grants?

After these awards, Alan G. Levin directly holds 79,565 shares of BioCryst Pharmaceuticals Common Stock. This figure reflects his position following the grant of 15,294 Restricted Stock Units and the separate stock option award disclosed in the Form 4 filing.

Are the BCRX equity awards to Alan G. Levin open-market purchases?

No, the equity awards to Alan G. Levin are not open-market purchases. They are automatic grants of Restricted Stock Units and stock options made under BioCryst’s Non-Employee Director Compensation Policy, representing compensation rather than discretionary buying in the market.

When do Alan G. Levin’s BCRX Restricted Stock Units vest?

The 15,294 Restricted Stock Units granted to Alan G. Levin will vest on the first anniversary of the grant date. This one-year vesting schedule comes from BioCryst Pharmaceuticals’ Non-Employee Director Compensation Policy, as described in the Form 4 footnotes.

What are the key terms of Alan G. Levin’s BCRX stock option grant?

Alan G. Levin received an automatic stock option grant for 33,540 shares of BioCryst Common Stock at an exercise price of $8.5000 per share. These options expire on June 11, 2036, providing a long-dated incentive tied to future share performance.

Under what policy were these BCRX director awards granted?

Both the Restricted Stock Units and stock options were granted under BioCryst Pharmaceuticals’ Non-Employee Director Compensation Policy. The policy governs automatic equity awards for non-employee directors, including vesting terms and option grants, as referenced directly in the Form 4 footnotes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEVIN ALAN G

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		15,294(1)	A	$0	79,565	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Automatic Stock Option Grant(2)	$8.5	06/11/2026		A		33,540		06/11/2027	06/11/2036	Common Stock	33,540	$0	33,540	D

Explanation of Responses:

1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

2. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

	/s/ Alane P. Barnes, by power of attorney	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)